<code id='48AB382FC7'></code><style id='48AB382FC7'></style>
    • <acronym id='48AB382FC7'></acronym>
      <center id='48AB382FC7'><center id='48AB382FC7'><tfoot id='48AB382FC7'></tfoot></center><abbr id='48AB382FC7'><dir id='48AB382FC7'><tfoot id='48AB382FC7'></tfoot><noframes id='48AB382FC7'>

    • <optgroup id='48AB382FC7'><strike id='48AB382FC7'><sup id='48AB382FC7'></sup></strike><code id='48AB382FC7'></code></optgroup>
        1. <b id='48AB382FC7'><label id='48AB382FC7'><select id='48AB382FC7'><dt id='48AB382FC7'><span id='48AB382FC7'></span></dt></select></label></b><u id='48AB382FC7'></u>
          <i id='48AB382FC7'><strike id='48AB382FC7'><tt id='48AB382FC7'><pre id='48AB382FC7'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:9
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In